Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification

被引:0
|
作者
Song, Byeong Geun [1 ]
Kim, Aryoung [1 ]
Goh, Myung Ji [1 ]
Kang, Wonseok [1 ]
Gwak, Geum-Youn [1 ]
Paik, Yong-Han [1 ]
Choi, Moon Seok [1 ]
Lee, Joon Hyeok [1 ]
Sinn, Dong Hyun [1 ]
机构
[1] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea
关键词
Steatotic liver disease; Metabolic dysfunction-associated steatotic liver disease; Nonalcoholic fatty liver disease; Metabolic dysfunction-associated fatty liver disease; Hepatocellular carcinoma; CONSENSUS STATEMENT; METABOLIC SYNDROME; CANCER; NAFLD; MORTALITY; FIBROSIS; ALCOHOL; OBESITY; HCC;
D O I
10.1159/000538301
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Steatotic liver disease (SLD) is a new overarching term proposed to replace nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease. Subclassification includes metabolic dysfunction-associated SLD (MASLD), MASLD with increased alcohol intake (MetALD), and cryptogenic SLD. This study aimed to investigate whether SLD and its subclassification could stratify hepatocellular carcinoma (HCC) risk. Methods: A cohort of 85,119 adults without viral hepatitis or heavy alcohol intake was analyzed for the risk of HCC according to SLD and its subclassification. The fibrosis-4 (FIB-4) index was used to estimate the degree of liver fibrosis. Results: During a median follow-up of 11.9 years, HCC was diagnosed in 123 individuals. The incidence rate of HCC per 1,000 person-years was higher in individuals with SLD than in those without SLD (0.197 vs. 0.071, p < 0.001), with an adjusted hazard ratio of 2.02 (95% confidence interval: 1.40-2.92). The HCC incidence rate per 1,000 person-years was 0, 0.180, and 0.648 for cryptogenic SLD, MASLD, and MetALD, respectively. When participants with SLD was further stratified by the FIB-4 index, the HCC incidence rate per 1,000 person-years was 0.074 for SLD with FIB-4 < 1.3 and 0.673 for SLD with FIB-4 >= 1.3. Of note, HCC risk was substantially high (HCC incidence rate: 1.847 per 1,000 person-years) for MetALD with FIB-4 >= 1.3. Conclusions: HCC risk was different by SLD and its subclassification. The utilization of SLD and its subclassification can aid in stratifying HCC risk and facilitate the identification of individuals requiring interventions to mitigate the risk of HCC.<br /> (c) 2024 The Author(s).Published by S. Karger AG, Basel
引用
收藏
页码:561 / 571
页数:11
相关论文
共 50 条
  • [31] Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma
    El-Serag, HB
    Tran, T
    Everhart, JE
    GASTROENTEROLOGY, 2004, 126 (02) : 460 - 468
  • [32] Chemoprevention of hepatocellular carcinoma associated with metabolic dysfunction-associated steatotic liver disease: an updated review
    Dickinson, Averie
    Dinani, Amreen
    Wegermann, Kara
    HEPATOMA RESEARCH, 2024, 10
  • [33] Prognostic Impact of Metabolic Syndrome and Steatotic Liver Disease in Hepatocellular Carcinoma Using Machine Learning Techniques
    Gil-Rojas, Sergio
    Suarez, Miguel
    Martinez-Blanco, Pablo
    Torres, Ana M.
    Martinez-Garcia, Natalia
    Blasco, Pilar
    Torralba, Miguel
    Mateo, Jorge
    METABOLITES, 2024, 14 (06)
  • [34] Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
    Nakamura, Toru
    Masuda, Atsutaka
    Nakano, Dan
    Amano, Keisuke
    Sano, Tomoya
    Nakano, Masahito
    Kawaguchi, Takumi
    CELLS, 2025, 14 (06)
  • [35] Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
    Wang, Yumin
    Fleishman, Joshua S.
    Li, Tongda
    Li, Yulin
    Ren, Zhao
    Chen, Jichao
    Ding, Mingchao
    FRONTIERS IN PHARMACOLOGY, 2024, 14
  • [36] Statin Use and Risk of Hepatocellular Carcinoma and Liver Fibrosis in Chronic Liver Disease
    Choi, Jonggi
    Nguyen, Vy H.
    Przybyszewski, Eric
    Song, Jiunn
    Carroll, Allison
    Michta, Megan
    Almazan, Erik
    Simon, Tracey G.
    Chung, Raymond T.
    JAMA INTERNAL MEDICINE, 2025,
  • [37] Alcoholic Liver Disease High Risk or Low Risk for Developing Hepatocellular Carcinoma?
    Joshi, Kartik
    Kohli, Anita
    Manch, Richard
    Gish, Robert
    CLINICS IN LIVER DISEASE, 2016, 20 (03) : 563 - +
  • [38] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study
    Kim, Gi-Ae
    Jeong, Seogsong
    Jang, Heejoon
    Lee, Dong Hyeon
    Joo, Sae Kyung
    Kim, Won
    LIVER CANCER, 2024, 13 (04) : 426 - 437
  • [39] Steatotic liver disease, MASLD and risk of chronic kidney disease
    Bilson, Josh
    Mantovani, Alessandro
    Byrne, Christopher D.
    Targher, Giovanni
    DIABETES & METABOLISM, 2024, 50 (01)
  • [40] Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study
    Lin, Ming
    Gao, Bowen
    Peng, Mengnan
    Chen, Xuefang
    Xiao, Huanming
    Shi, Meijie
    Zhang, Xiujuan
    Zeng, Folai
    Chi, Xiaoling
    FRONTIERS IN PHYSIOLOGY, 2024, 15